Max NisenNIH/Lilly halting trial of its antibody therapy in hospitalized patients. Not related to safety pause -- lack of efficacy. Reason to expect it'd work better earlier (confirmatory trial ongoing) but not a positive for its commercial prospects/impact.
We hit the road with NPR Education Reporter Elissa Nadworny. She's been on a weekslong road trip to get an up-close view of how colleges across the U.S. are handling the pandemic. On today's show, she tells us how one university has been using mass...
As we get closer to an important data readout from our COVID-19 vaccine program, I wanted to speak directly to the billions of people, millions of businesses and hundreds of governments around the world that are investing their hopes in a safe and...
Max NisenPfizer out with a very clear statement on vaccine timing. If it gets positive data (regardless of when it comes) it will apply for an EUA only when it has enough safety data to meet FDA standard -- which it expects would be the third week of November.